FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048896472> ?p ?o ?g. }

• W3048896472 endingPage "126" @default.
• W3048896472 startingPage "117" @default.
• W3048896472 abstract "Objectives The most common form of pediatric cancer is acute lymphoblastic leukemia (ALL). Magnetic resonance (MR) neuroimaging studies have revealed leukoencephalopathy (LE) in pediatric ALL, but the impact of LE on long-term neurocognitive performance remains unknown. This study aims to objectively characterize the prevalence, extent, and intensity of LE, and their association with later neurocognitive performance. Materials and Methods Pediatric patients (N = 377) treated for ALL without irradiation underwent MR neuroimaging at 4 time points throughout therapy (end of remission induction [MR1], end of consolidation [MR2], and week 31 [MR3] and week 120 [end therapy, MR4] of continuation treatment) and neurocognitive evaluations at the end of therapy and 2 years later. Generalized estimation equation models with logit link were developed to explore the association between LE prevalence and extent with time points throughout therapy, age at diagnosis (≤5 years or >5 years), treatment risk arm (low risk or standard/high risk), and sex. General linear models were also developed to investigate the association between neuroimaging metrics during treatment and neurocognitive performance at 2-year follow-up. Results The prevalence of LE was greatest (22.8%, 74/324) after consolidation therapy. The prevalence of LE increased at MR2 relative to MR1 regardless of treatment risk arm (both P 's < 0.001), age group (both P 's < 0.001), or sex (male, P < 0.001; female, P = 0.013). The extent of white matter affected also increased at MR2 relative to MR1 regardless of treatment risk arm (standard/high risk, P < 0.001; low risk, P = 0.004), age group (both P 's < 0.001), or sex (male, P < 0.001; female, P = 0.001). Quantitative relaxation rates were significantly longer in LE compared with that in normal-appearing white matter in the same examination (T1, P < 0.001; T2, P < 0.001). The LE prevalence early in therapy was associated with increased parent ratings of conduct problems ( P = 0.039) and learning difficulties ( P = 0.036) at 2-year follow-up compared with that at the end of therapy. A greater extent of LE early in therapy was associated with decreasing performance on a measure of processing speed ( P = 0.003) from the end of therapy to 2-year follow-up. A larger extent of LE at the end of therapy was associated with decreased performance in reading ( P = 0.004), spelling ( P = 0.003), and mathematics ( P = 0.019) at 2-year follow-up and increasing problems with attention (omissions, P = 0.045; β, P = 0.015) and memory (list A total recall, P = 0.010) at 2-year follow-up compared with that at the end of therapy. Conclusions In this large cohort of pediatric patients treated for ALL without irradiation, asymptomatic LE during therapy can be seen in almost a quarter of patients, involves as much as 10% of the white matter volume, and is associated with decreasing neurocognitive performance, increasing parent reports of conduct problems, and learning difficulties in survivors." @default.
• W3048896472 created "2020-08-18" @default.
• W3048896472 creator A5014809844 @default.
• W3048896472 creator A5017202683 @default.
• W3048896472 creator A5049391890 @default.
• W3048896472 creator A5050427262 @default.
• W3048896472 creator A5075709087 @default.
• W3048896472 creator A5077442433 @default.
• W3048896472 creator A5080224930 @default.
• W3048896472 creator A5086660536 @default.
• W3048896472 date "2020-08-10" @default.
• W3048896472 modified "2023-10-16" @default.
• W3048896472 title "Characterization of Leukoencephalopathy and Association With Later Neurocognitive Performance in Pediatric Acute Lymphoblastic Leukemia" @default.
• W3048896472 cites W1558704041 @default.
• W3048896472 cites W1964584556 @default.
• W3048896472 cites W1970461946 @default.
• W3048896472 cites W1984486655 @default.
• W3048896472 cites W1988090699 @default.
• W3048896472 cites W1998072086 @default.
• W3048896472 cites W2010454129 @default.
• W3048896472 cites W2012287241 @default.
• W3048896472 cites W2034574098 @default.
• W3048896472 cites W2040160279 @default.
• W3048896472 cites W2047713955 @default.
• W3048896472 cites W2058159766 @default.
• W3048896472 cites W2059999488 @default.
• W3048896472 cites W2062170532 @default.
• W3048896472 cites W2068438606 @default.
• W3048896472 cites W2095746088 @default.
• W3048896472 cites W2098676147 @default.
• W3048896472 cites W2099191228 @default.
• W3048896472 cites W2111165085 @default.
• W3048896472 cites W2127038160 @default.
• W3048896472 cites W2130077038 @default.
• W3048896472 cites W2130190421 @default.
• W3048896472 cites W2130902516 @default.
• W3048896472 cites W2135172942 @default.
• W3048896472 cites W2135706738 @default.
• W3048896472 cites W2139498473 @default.
• W3048896472 cites W2150189667 @default.
• W3048896472 cites W2162216421 @default.
• W3048896472 cites W2164863629 @default.
• W3048896472 cites W2272185880 @default.
• W3048896472 cites W2415263224 @default.
• W3048896472 cites W2516761392 @default.
• W3048896472 cites W2795084708 @default.
• W3048896472 cites W2889837535 @default.
• W3048896472 cites W2913702059 @default.
• W3048896472 cites W2920825015 @default.
• W3048896472 cites W2921767079 @default.
• W3048896472 cites W2942626124 @default.
• W3048896472 cites W2950794870 @default.
• W3048896472 cites W2975961301 @default.
• W3048896472 cites W2991695207 @default.
• W3048896472 doi "https://doi.org/10.1097/rli.0000000000000715" @default.
• W3048896472 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8059361" @default.
• W3048896472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32769417" @default.
• W3048896472 hasPublicationYear "2020" @default.
• W3048896472 type Work @default.
• W3048896472 sameAs 3048896472 @default.
• W3048896472 citedByCount "4" @default.
• W3048896472 countsByYear W30488964722021 @default.
• W3048896472 countsByYear W30488964722023 @default.
• W3048896472 crossrefType "journal-article" @default.
• W3048896472 hasAuthorship W3048896472A5014809844 @default.
• W3048896472 hasAuthorship W3048896472A5017202683 @default.
• W3048896472 hasAuthorship W3048896472A5049391890 @default.
• W3048896472 hasAuthorship W3048896472A5050427262 @default.
• W3048896472 hasAuthorship W3048896472A5075709087 @default.
• W3048896472 hasAuthorship W3048896472A5077442433 @default.
• W3048896472 hasAuthorship W3048896472A5080224930 @default.
• W3048896472 hasAuthorship W3048896472A5086660536 @default.
• W3048896472 hasBestOaLocation W30488964722 @default.
• W3048896472 hasConcept C118552586 @default.
• W3048896472 hasConcept C126322002 @default.
• W3048896472 hasConcept C126838900 @default.
• W3048896472 hasConcept C143409427 @default.
• W3048896472 hasConcept C169900460 @default.
• W3048896472 hasConcept C172467417 @default.
• W3048896472 hasConcept C187212893 @default.
• W3048896472 hasConcept C2778583010 @default.
• W3048896472 hasConcept C58693492 @default.
• W3048896472 hasConcept C71924100 @default.
• W3048896472 hasConceptScore W3048896472C118552586 @default.
• W3048896472 hasConceptScore W3048896472C126322002 @default.
• W3048896472 hasConceptScore W3048896472C126838900 @default.
• W3048896472 hasConceptScore W3048896472C143409427 @default.
• W3048896472 hasConceptScore W3048896472C169900460 @default.
• W3048896472 hasConceptScore W3048896472C172467417 @default.
• W3048896472 hasConceptScore W3048896472C187212893 @default.
• W3048896472 hasConceptScore W3048896472C2778583010 @default.
• W3048896472 hasConceptScore W3048896472C58693492 @default.
• W3048896472 hasConceptScore W3048896472C71924100 @default.
• W3048896472 hasIssue "2" @default.
• W3048896472 hasLocation W30488964721 @default.
• W3048896472 hasLocation W30488964722 @default.
• W3048896472 hasLocation W30488964723 @default.
• W3048896472 hasOpenAccess W3048896472 @default.

• next